



# Dr. med. Antoine Leimgruber

Spécialiste FMH en Médecine Nucléaire  
Spécialiste FMH en Radiologie  
Physicien EPFL

---

## Sprachen

FR,EN,ES

## Berufserfahrung

seit 2021	Director of Development Swiss Medical Network, Nuclear Medicine
seit 2021	
seit 2019	Co-Founder, Biopsomic SA
2015-2021	Head of Nuclear Medicine and Oncology (Hopital Riviera-Chablais)
2007-2014	Fellowships, Lausanne University Hospital, Peter MacCallum Cancer Centre, Austin Health, Center for Molecular Imaging Research & Center for Systems Biology, Harvard Medical School
2001-2006	Research Associate, Molecular Modelling Group, Swiss Institute of Bioinformatics and Ludwig Institute Lausanne
2000	Project Engineer, Picture Archiving and Communication System, Service of Radiology, Lausanne University Hospital
1998-1999	Financial mathematics consultant, Time-Steps Ltd, Zurich

## Ausbildung

2007-2015	Specialist training: <ul style="list-style-type: none"><li>• Hybrid imaging fellow, Department of Cancer Imaging, Peter MacCallum Cancer Centre (Prof Hicks, Melbourne)</li><li>• Nuclear Medicine Registrar, Service of Nuclear Medicine &amp; Ludwig Institute (Prof Rowe and Scott, Melbourne Australia)</li><li>• Fellow, Service of Nuclear Medicine, Lausanne University Hospital (Prof Prior, Switzerland)</li><li>• Resident, Service of Radiology, Lausanne University Hospital (Prof Schnyder, Meuli, Switzerland)</li><li>• Postdoctoral Fellow, Center for Molecular Imaging Research &amp; Center for Systems Biology (Prof Pittet &amp; Weissleder, Harvard Medical School, USA)</li></ul>
2000-2007	Non-specialist training: <ul style="list-style-type: none"><li>• Lausanne University Hospital</li><li>• Massachusetts General Hospital (Boston USA)</li><li>• Oncology Institute of Oriental Bolivia (Santa Cruz Bolivia)</li><li>• Ambulatorio Dr David Espinoza Rojas (Nueva Esparta, Venezuela)</li></ul>

## Mitgliedschaften

- Fédération des médecins suisses (FMH)
- Société vaudoise de médecine (SVM)

- Société suisse de médecine nucléaire (SSMN)
- Société Suisse de radiologie (SSR) European Neuroendocrine Tumor Society
- Australian and New Zealand Society of Nuclear Medicine (ANZSNM)
- Radiological Society of North America (RSNA)
- European Neuroendocrine Tumor Society (ENETS)
- Vaud State Academic Society

## Publikationen

Lobb RJ, van Amerongen R, Wen Wen S, Wong CSF, Wiegman AP, Hstie M, Norris E, Siva S, Everitt S, Fong K, Gorman J, **Leimgruber A** and Möller A, *An epithelial-to-mesenchymal transition induced multi-protein exosome signature prognosticates patient outcome in non-small cell lung cancer*, in prep.

Gatta R, Depeursinge A, Ratib O, Michielin O, **Leimgruber A**, *Integrating radiomics into holomics for personalised oncology: from algorithms to bedside*, European Radiology Exp, 2020 Feb 07;4(11) - ~10 citations

**Leimgruber A**, Hickson K, Lee ST, Gan HK, Cher LM, Sachinidis JLO, O'Keefe GJ, Scott AM, *Spatial and quantitative mapping of glycolysis and hypoxia in glioblastoma as a predictor of radiotherapy response and sites of relapse*, EJNMMI, 2020 Feb 5;47(1476-1485) - ~10 citations

Wen Wen S, Everitt SJ, Bedö J, Chabrot M, Ball DL, Solomon B, MacManus M, Hicks RJ, Möller A and **Leimgruber A**, *Spleen volume variation in patients with locally advanced non-small cell lung cancer receiving platinum-based chemo-radiotherapy*, PLoS One. 2015 Nov 24;10(11) - ~15 citations

Lobb RJ, Becker M, Wen Wen S, Wong CSF, Wiegman AP, **Leimgruber A**, Möller A, *Optimized Exosome Isolation Protocol for Cell Culture Supernatant and Human Plasma*, J Extracell Vesicles. 2015 Jul 17;4 - ~800+ citations

**Leimgruber A**, Möller A, Everitt S, Chabrot M, Ball D, Solomon B, MacManus M and Hicks R, *Effect of platinum-based chemoradiotherapy on cellular proliferation in bone marrow and spleen, estimated by FLT-PET/CT in patients with locally advanced non-small cell lung cancer*, J Nucl Med. 2014 May 27;55(7) - ~30 citations & Alavi-Mandell award

**Leimgruber A**, Ferber M, Irving M, Hussain-Kahn H, Wieckowski S, Rufer N, Zoete V and Michielin O, *TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires*, PloS One. 2011;6(10) - ~20 citations

Gambarota G, Perazzolo C, **Leimgruber A**, Meuli R, Mangin P, Augsburg M and Grabherr S, *Non-invasive detection of dissolved cocaine in wine bottles by magnetic resonance spectroscopy*, Drug Test Anal. 2010 Sep 30.

**Leimgruber A**, Berger C, Cortez-Retamozo V, Etzrodt M, Newton A, Waterman P, Figueiredo J, Kohler R, Elpek N, Mempel T, Swirski F, Nahrendorf M, Weissleder R and Pittet M, *Behavior of endogenous tumor-associated macrophages assessed in vivo using a functionalized nanoparticle*, Neoplasia. 2009 May; 11(5) - ~100 citations & journal cover

Derré L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, **Leimgruber A**, Zoete V, Romero P, Michielin O, Speiser D and Rufer N, *Structurally distinct TCRs confer similar recognition of the tumor-specific epitope NY-ESO-1157-165 by interacting with its central Met/Trp residues*, Proc Natl Acad Sci U S A. 2008 Sep 30;105(39) - ~40 citations

Derré L, Ferber M, Touvrey C, Devevre E, Zoete V, **Leimgruber A**, Romero P, Michielin O, Lévy F and Speiser D, *A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide*, J Immunol, 2007 Dec 1;179(11) - ~30 citations

**Leimgruber A**, Ostermann S, Yeon EJ, Buff E, Maeder P, Stupp R and Meuli R, *Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial*, Int J Radiat Oncol Biol Phys, 2006 Mar 1;64(3) - ~40 citations

## Akkreditierung

[Clinique de Genolier](#)

## Fachgebiete

[Nuklearmedizin](#)

[Radiologie](#)

## Kontakt

**Clinique de Genolier**

Route du Muids 3

1272 Genolier

T +41 22 366 93 15

[aleimgruber@swissmedical.net](mailto:aleimgruber@swissmedical.net)

[vCard herunterladen](#)

T +41 79 264 29 09

[vCard herunterladen](#)